Cardiovascular protection: a breakthrough for high-risk patients?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Endocrinology

Background:

• Angiotensin II significantly impacts cardiovascular health, making its inhibitors crucial for preventing cardiovascular disease.
• The renin-angiotensin system plays a key role in cardiovascular regulation and disease progression.

Purpose of the Study:

• To compare the efficacy and tolerability of telmisartan versus ramipril in high-risk patients.
• To evaluate the added benefit of combination therapy (telmisartan plus ramipril) compared to monotherapy.

Main Methods:

• The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) enrolled patients with vascular disease or diabetes at high cardiovascular risk.
• Comparison of telmisartan (angiotensin II receptor blocker) with ramipril (angiotensin-converting enzyme inhibitor).

Main Results:

• Telmisartan demonstrated noninferiority to ramipril in preventing major cardiovascular events.
• Telmisartan exhibited superior tolerability compared to ramipril.
• Combination therapy with telmisartan and ramipril did not provide further cardiovascular event reduction beyond monotherapy, despite greater blood pressure lowering.

Conclusions:

• Telmisartan is a well-tolerated and effective alternative to ramipril for cardiovascular risk reduction.
• The study suggests potential endothelial benefits of renin-angiotensin system blockade beyond blood pressure reduction.